For treatment of established acute lung injury or ARDS due to COVID 19, NKCC1 inhibitors, anti-TNF alpha treatment, aspirin, and statins need to be included in prospective randomized placebo controlled trials. This evidence concerns the gene SLC12A2 and acute respiratory distress syndrome.